Skip to main content
Download PDF

Altered gut microbiota and its association with inflammation in patients with chronic thromboembolic pulmonary hypertension: a single-center observational study in Japan

BMC Pulmonary Medicine volume 22, Article number: 138 (2022) Cite this article

Abstract

Background

The pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH) is considered to be associated with chronic inflammation; however, the underlying mechanism remains unclear. Recently, altered gut microbiota were found in patients with pulmonary arterial hypertension (PAH) and in experimental PAH models. The aim of this study was to characterize the gut microbiota in patients with CTEPH and assess the relationship between gut dysbiosis and inflammation in CTEPH.

Methods

In this observational study, fecal samples were collected from 11 patients with CTEPH and 22 healthy participants. The abundance of gut microbiota in these fecal samples was assessed using 16S ribosomal ribonucleic acid (rRNA) gene sequencing. Inflammatory cytokine and endotoxin levels were also assessed in patients with CTEPH and control participants.

Results

The levels of serum tumor necrosis factor-α (TNF-α), interleukin (IL)-6, IL-8, and macrophage inflammatory protein (MIP)-1α were elevated in patients with CTEPH. Plasma endotoxin levels were significantly increased in patients with CTEPH (P < 0.001), and were positively correlated with TNF-α, IL-6, IL-8, and MIP-1α levels. The 16S rRNA gene sequencing and the principal coordinate analysis revealed the distinction in the gut microbiota between patients with CTEPH (P < 0.01) and control participants as well as the decreased bacterial alpha-diversity in patients with CTEPH. A random forest analysis for predicting the distinction in gut microbiota revealed an accuracy of 80.3%.

Conclusion

The composition of the gut microbiota in patients with CTEPH was distinct from that of healthy participants, which may be associated with the elevated inflammatory cytokines and endotoxins in CTEPH.

Peer Review reports

Background

Chronic thromboembolic pulmonary hypertension (CTEPH) is a type of pulmonary hypertension (PH) categorized as group 4 PH [1,2,3]. CTEPH is characterized by the occlusion of the pulmonary arteries with chronic thrombi [1], which leads to the elevation of pulmonary arterial pressure, right heart failure, and death [3]. Specific treatments such as pulmonary endarterectomy, balloon pulmonary angioplasty, and medical treatment for CTEPH have been developed since the 1980s, and advances in the diagnosis and treatment algorithms have contributed to the improved prognosis of CTEPH [4, 5]. Despite these advances, CTEPH is still incurable [2]. Some cases of CTEPH complicated by low cardiac function, persistent PH after specific therapies, renal failure, and malignancy are still at a high risk for mortality [4]. The detailed mechanism of CTEPH development is not fully understood; therefore, research focusing on the pathogenesis of CTEPH is required [3].

Chronic inflammation is conceptually associated with the development of CTEPH [6]. Associated medical conditions, such as inflammatory bowel diseases, splenectomy, and malignancy, can be closely related to pulmonary vascular remodeling and the development of CTEPH [6,7,8]. Elevated inflammatory cytokines in CTEPH [6, 9] may be associated with its pathogenesis [3], hemodynamics, and prognosis [10, 11]. In chronic organized thrombi in CTEPH, which is a distinct pathological feature compared to the other types of PH [1,2,3], the accumulation of inflammatory cells, such as lymphocytes, neutrophils, and macrophages [9, 12], are observed. Despite this knowledge, the mechanism of chronic inflammation in CTEPH is not yet fully understood.

Abnormal gut microbiota (dysbiosis) is associated with the development of cardiovascular diseases [13,14,15,16]. Gut dysbiosis can lead to translocation of metabolic products and bacterial components from the gut lumen into the bloodstream and can induce an inflammatory processes including activation of macrophages, release of inflammatory cytokines, abnormal aggregation of platelets, and formation of foam cells [13,14,15]. The induced inflammation can be related to the development of systemic hypertension, atherosclerosis, coronary artery disease, and chronic heart failure [14, 15, 17]. Recent studies suggest that gut dysbiosis appears in experimental animal PH models [18,19,20,21] and in patients with pulmonary arterial hypertension (PAH) [22], and may have a causative role in the development of PAH [18, 21]. We hypothesized that gut dysbiosis is also present in CTEPH and is related to the chronic inflammation and pathogenesis of CTEPH.

The aim of this study was to characterize the gut microbiota in patients with CTEPH. In this study, fecal samples were collected from patients with CTEPH and control participants, and the composition of gut microbiota was analyzed by 16S rRNA sequencing. In addition, the relationship between gut dysbiosis and elevated inflammatory cytokines was also assessed.

Methods

Patients with CTEPH and control participants

A total of 11 patients diagnosed with CTEPH in Chiba University Hospital were enrolled from October 2017 to January 2020 in this study. Clinical data of patients with CTEPH at diagnosis were analyzed in this study. All of the patients with CTEPH were diagnosed according to the criteria of the 2015 European Society of Cardiology/European Respiratory Society guidelines [23]: 1) mean pulmonary arterial pressure ≥ 25 mmHg; 2) persistent pulmonary embolism confirmed by imaging modalities; 3) symptoms, such as dyspnea and chest pain; and 4) persistent pulmonary embolism lasting > 3 months resisting effective anticoagulation. Hemodynamic data in all patients were assessed using right heart catheterization. The control participants were selected from the database at the National Institutes of Biomedical Innovation, Health and Nutrition and matched with patients with CTEPH in terms of age, sex, and body mass index (BMI) [24].

Fecal sample collection

Fecal sample collection and deoxyribose nucleic acid (DNA) isolation were performed as previously reported [25]. The fecal samples from patients with CTEPH were collected within 1 week before and after right heart catheterization upon diagnosis at hospital admission, whereas the samples from the control participants were collected in their houses. The time points during the day depended on the participant’s decisions. The fecal samples were placed in tubes containing guanidine thiocyanate solution (Techno-Suruga Laboratory Co., Ltd., Shizuoka, Japan), which were transferred to refrigerators within 5 min after collection. The samples were stored and transported at 4 °C before DNA isolation. DNA was isolated from the fecal samples using the beating method.

16S ribosomal ribonucleic acid sequencing

Amplification and sequencing of bacterial 16S rRNA was performed according to our previous reports [25]. The V3-V4 region of the 16S rRNA gene of bacteria was amplified by polymerase chain reaction (PCR) using the following primers: forward, 5′-TCGTCGGCAGCGTCAGATGTGTATAAGCGACAGCCTACGGGNGGCWGCAG-3′, and reverse, 5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC-3′, which was followed by the addition of the sequencing adapters. The amplicons were sequenced using the Illumina MiSeq platform (Illumina Inc., San Diego, CA, USA). A total of 10,000 reads per sample were randomly selected for further analysis. Samples with insufficient read numbers were re-sequenced, and those with repeated insufficient read numbers were excluded.

Bioinformatics analysis

The obtained paired-end FASTQ data were trimmed and merged before the selection of operational taxonomic units (OTUs). The OTU classification and diversity analyses were performed using the QIIME pipeline (v1.9.1) [26]. All the steps from FASTQ trimming to gut microbiota diversity analysis were automatically performed according to a previously described method [27]. The OTUs were clustered against the SILVA 128 reference database [28] at 97% similarity using the USEARCH algorithm [29]. Taxonomic classification to the genus-level taxa (hereafter referred as genera) was performed using the SILVA 128 reference database. The specific taxonomy names were based on the SILVA database phylogenetic classification standard (https://www.arb-silva.de/browser/ssu/).

Assessment of plasma endotoxin

Plasma endotoxin levels were measured using a Toxin Sensor Chromogenic LAL Endotoxin Assay Kit (GenScript, Piscataway, NJ, USA) according to the manufacturer’s protocol. Plasma samples were collected from the participants, and standards were incubated with Limulus amebocyte lysate, which was followed by incubation with a chromogenic substrate. Subsequently, the reaction was stopped by the stop solution, and the color-stabilizers were added. Finally, the absorbance at 545 nm was read using a plate reader, and the serum concentration of endotoxin was calculated based on the standard curve.

Assessment of inflammatory cytokines

Inflammatory cytokines in serum samples were analyzed using the Bio-plex Pro Human Cytokine 27-plex assay (Bio-Rad, Hercules, CA, US), according to the manufacturer’s instructions. A four-fold dilution of serum was incubated with beads and antibodies, and the fluorescence intensity was measured using a Bio-plex system (Bio-Rad). The data were analyzed using Bio-Plex Manager Software ver. 6.1 (Bio-Rad) to calculate the concentration of cytokines based on a standard curve.

Statistical analysis

The output of the QIIME pipeline in the Biom table format was imported and analyzed using R version 3.5.1 (The R foundation for Statistical Computing, Vienna, Austria). The alpha-diversity indices were calculated using the estimate_richness function in the “phyloseq” R-package. The beta-diversity index, calculated by Bray–Curtis distance using genus-level data, was generated using the vegdist function in the “vegan” R-package. Principal coordinate analysis (PCoA) was performed using the dudi.pco function in the “ade4” R-package. Covariates of gut microbiome β-diversity were identified by calculating the association between continuous or categorical phenotypes and genus-level community coordinate with MANOVA and linear correlations for categorical and continuous variables, respectively. PCoA figures were created using the R package “ggplot2.”

Random forest classification analysis was performed to confirm the potential use of the gut-microbiota community structure as a biomarker to distinguish between patients with CTEPH and the control participants. The train function of the “caret” R package was used for random forest classification analysis [30]. The dataset of the classification random forest prediction model was assessed using all data as the training set. In the dataset, descriptors that showed near-zero-variance and absolute correlations of > 0.90 were identified and excluded by calculating the frequency ratio using the nearZeroVar function and by creating a correlation matrix using the findCorrelation function in the “caret” R package. Finally, descriptors which significantly contributed to the prediction accuracy were selected using the Boruta algorithm [31].

Data were analyzed using statistical software, (GraphPad Prism 9.0.0, GraphPad Software Inc. San Diego, CA, USA). Comparison between the two groups was performed using the Mann–Whitney U-test. The correlation between the two variates was assessed by Spearman’s rank correlation. Data are described as mean ± standard deviation unless otherwise stated. Statistical significance (P) was set at < 0.05.

Assessment of dietary habits

Dietary intake was evaluated using a brief self-administered diet history questionnaire (BDHQ), which was developed and validated for use in the Japanese population [32, 33]. The information regarding the dietary habits of all participants were collected around the period when the fecal samples were collected.

Results

Characteristics of the participants

The backgrounds of patients with CTEPH and the control paticipants are shown in Table 1. There were no differences in age, sex, and BMI between the control and CTEPH groups because of the matching. One patient had a history of prostate cancer, whereas another patient had a history of Crohn’s disease. None of the participants had implantable medical devices. Eight of the 11 (72.7%) patients with CTEPH had been medically treated with a soluble guanylate stimulator before our diagnosis. All of the 11 patients with CTEPH received anticoagulants at diagnosis (nine patients, warfarin; one patient each rivaroxaban and edoxaban). None of the patients had undergone specific invasive treatments, including pulmonary endarterectomy and pulmonary balloon angioplasty, before the fecal samples were collected. Six (54.5%) patients with CTEPH and two (9.01%) control participants received proton pump inhibitors (PPIs), and the usage was higher in patients with CTEPH (P < 0.01). Dietary intake did not differ between the two groups (Additional files 1 and 2).

Table 1 Characteristics of patients with CTEPH and control participants
Full size table

Elevated cytokines in patients with CTEPH

Inflammatory cytokines were first assessed using Bio-plex cytokine assays. Serum tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8, and macrophage inflammatory protein (MIP)-1α levels were significantly higher in patients with CTEPH than in the control participants (Figs. 1a–d).

Fig. 1
figure 1

Elevated cytokine levels in chronic thromboembolic pulmonary hypertension and the correlation with serum endotoxin levels. Inflammatory cytokines in the serum are measured using Bio-plex cytokine assays (Bio-Rad). a Serum tumor necrosis factor (TNF)-α levels. b Serum interleukin (IL)-6 levels. c Serum IL-8 levels. d Serum macrophage inflammatory protein (MIP)-1α levels

Full size image

Elevated endotoxin levels in patients with CTEPH

Subsequently, the plasma concentration of endotoxin was assessed in patients with CTEPH and the control participants. Endotoxin is a lipopolysaccharide, a component of the cell membrane of gram-negative bacteria, that can be translocated from the gut lumen to the bloodstream and can induce the expression of inflammatory cytokines and the development of cardiovascular diseases [15]. The endotoxin concentration was significantly higher in patients with CTEPH than in the control participants (P < 0.001, Fig. 2a). Serum TNF-α, IL-6, IL-8, and MIP-1α levels were positively correlated with plasma endotoxin levels (TNF-α: r = 0.492, P < 0.01; IL-6: r = 0.565, P < 0.01; IL-8: r = 0.425, P < 0.05; and MIP-1α: r = 0.481, P < 0.01, Figs. 2b–e).

Fig. 2
figure 2

Elevated serum endotoxin level in patients with chronic thromboembolic pulmonary hypertension. a Plasma endotoxin levels in the control participants and in patients with CTEPH. b to e show scatter plots between endotoxin and inflammatory cytokine levels. b Tumor necrosis factor (TNF)-α and endotoxin (r = 0.492, P < 0.01) levels. c Interleukin (IL)-6 and endotoxin (r = 0.565, P < 0.01) levels. d IL-8 and endotoxin (r = 0.425, P < 0.05) levels. e Macrophage inflammatory protein (MIP)-1α and endotoxin (r = 0.481, P < 0.01) levels

Full size image

Gut microbiota alteration in patients with CTEPH

Subsequently, 16S rRNA sequencing was conducted to assess the composition of the gut microbiota in patients with CTEPH and the control participants. Regarding alpha-diversities, the number of OTUs and the Fisher index were significantly lower in patients with CTEPH than in the control participants (Figs. 3a and b). The PCoA analysis revealed a different composition of gut microbiota in patients with CTEPH than in the control participants (P < 0.01, Fig. 3c). Faecalibacterium, Roseburia, and Fusicatenibacter abundance levels were significantly decreased in patients with CTEPH (Figs. 3d–f). The endotoxin concentration was negatively correlated with the relative abundance of these bacteria (Faecalibacterium: r = -0.365, P < 0.05; Roseburia: r = -0.516, P < 0.01; and Fusicatenibacter: r = -0.397, P < 0.05, Figs. 3g–i).

Fig. 3
figure 3

Characteristics of gut microbiota in patients with chronic thromboembolic pulmonary hypertension. a and b show the alpha-diversity indexes: a Observed operational taxonomic unit (OTU) and b Fisher index. c Principal coordinates analysis (PCoA). d to f show the relative abundances of butyrate-producing bacteria: d Faecalibacterium; f Roseburia; and f Fusicatenibacter. g to i show scatter plots between the relative abundance of butyrate-producing bacteria and plasma endotoxin levels. g Faecalibacterium and endotoxin (r = -0.365, P < 0.05) levels. h Roseburia and endotoxin (r = -0.516, P < 0.01) levels. i Fusicatenibacter and endotoxin (r = -0.397, P < 0.05) levels

Full size image

Random forest analysis

Finally, a prediction model using random forests to distinguish the components of gut microbiota of patients with CTEPH from those of the control participants were created. The detection of the difference in the gut microbiota of the two groups through a classification random forest prediction model had an accuracy of 80.3%, sensitivity of 89.8%, and specificity of 58.9% (Fig. 4a). Bacteria that were affected as notable variables in this predictive model were Roseburia, Parabacteroides, Faecalibacterium, Prevotella, the Lachnospiraceae NK4A136 group, and Porphyromonas bacteria (Fig. 4b).

Fig. 4
figure 4

Random forest plot analysis for detecting differences in gut microbiota between the two groups. a Receiver operating characteristic (ROC) curve of the random forest model. The area under the curve (AUC) is 0.744, and the accuracy is 0.803. b The feature importance of the random forest model

Full size image

Discussion

This study is the first to characterize the gut microbiota of patients with CTEPH. The 16S rRNA sequencing analysis suggested a different composition of gut microbiota in patients with CTEPH compared to that in the control participants and a decreased alpha-diversity in patients with CTEPH; this finding was also supported by a random forest plot demonstrating the distinction with an accuracy of 80.3%. Plasma endotoxin levels were elevated in patients with CTEPH and were positively correlated with the levels of serum inflammatory cytokines, such as TNF-α, IL-6, IL-8, and MIP-1α. Collectively, our results suggest that patients with CTEPH have gut dysbiosis at diagnosis. In addition, the alteration of the gut microbial composition may be associated with the elevation of endotoxin and inflammatory cytokines.

The composition of gut microbiota in patients with CTEPH differed from that of the control participants. Recent studies have suggested that gut dysbiosis occurs in patients with PAH [22] and PH animal models, such as Sugen 5416/hypoxia [20, 21], monocrotaline [19], and hypoxia-induced PH models [18]. To the best of our knowledge, this is the first report to describe the characteristics of the gut microbiota in patients with CTEPH. The PCoA analysis revealed a difference in the composition of the gut microbiota between patients with CTEPH and the control participants, and the results of the random forest analysis supported this distinction. Kim et al. performed random forest analysis to detect the differences in gut microbiota between patients with PAH and control participants and reported an accuracy of 83% [22]. Thus, the analysis of gut microbiota might become a new tool for detecting PH, including CTEPH in the future.

Inflammatory cytokine levels were elevated in patients with CTEPH in this study. It is well known that patients with CTEPH have elevated levels of TNF-α [10, 34], IL-6 [9, 10], IL-8 [9, 35], and MIP-1α [9, 12], which are secreted by the activated macrophages. It has been reported that the accumulation of macrophages is dominant over that of neutrophils in the chronic organized thrombi of patients with CTEPH [36]. TNF-α can affect the coagulation via the elevation of mononuclear tissue factor levels [34] in CTEPH and may be related to the change from acute pulmonary embolism to CTEPH [37]. Von Haehling et al. reported that IL-6 is positively correlated with pulmonary vascular resistance [10]. High serum IL-8 levels have been reported to be related to the development of residual PH after pulmonary endarterectomy [35] and the poor survival of patients with CTEPH [11]. It seems that the macrophages and the cytokines released from macrophages may be associated with the pathogenesis of CTEPH.

Endotoxin levels were significantly higher in patients with CTEPH than in the control participants. Some reports have described elevated endotoxin levels in patients diagnosed with CTEPH [10] and PAH [38] and monocrotaline animal models [38], which supports our results. Endotoxins can translocate from the gut lumen into the bloodstream, which results from an increased intestinal permeability [15, 38]. It is also known that an increase in gut permeability occurs in patients with PAH [25, 26] and an experimental PH model [19]. The endotoxin level is an indirect indicator of increased gut permeability [39]; therefore, elevated endotoxin levels in this study might indicate the increase in gut permeability in patients with CTEPH. Notably, the relative abundances of Faecalibacterium, Roseburia, and Fusicatenibacter were reduced in patients with CTEPH and negatively correlated with the endotoxin levels in these patients and the control participants. Faecalibacterium, Roseburia, and Fusicatenibacter have several biological functions, including anti-inflammatory functions, to maintain intestinal homeostasis. Leclercq et al. reported that the relative abundance of Faecalibacterium was negatively correlated with gut permeability [40]. Roseburia protects the gut-barrier function via butyrate production and suppresses the intestinal inflammation induced by endotoxin by increasing regulatory T cells and the expression of anti-inflammatory cytokines [41, 42]. A decrease in Fusicatenibacter abundance is related to decreased levels of short-chain fatty acids, including butyrate, in patients with liver cirrhosis [43]. As a result of the important variables of the prediction model created through random forest analysis in this study, it was found that there was no association between Fusicatenibacter and the gut dysbiosis, but Faecalibacterium and Roseburia were important variables to characterize patients with CTEPH as in the comparative analysis results. The decrease in bacteria with protective roles for intestinal homeostasis and anti-inflammatory functions in CTEPH may be associated with chronic inflammation via the elevation of endotoxin and cytokine levels.

Endotoxin was positively correlated with inflammatory cytokines in this study. Endotoxin can activate macrophages and endothelial cells via the activation of nuclear factor-kappa B (NFκB) signaling [13, 15, 44, 45]. The activation of NFκB signaling may be associated with the pathogenesis of CTEPH. The NFκB signaling is activated in the endothelial cells within organized thrombi in patients with CTEPH [46], and the expression of inflammatory cytokines is increased [46, 47]. The translocation of endotoxin induced by gut dysbiosis, which has recently been called “metabolic endotoxemia” [48], is associated with chronic low-grade inflammation and the development of cardiovascular diseases [13, 15]. Metabolic endotoxemia may also be related to the pathogenesis of CTEPH.

Although gut dysbiosis in patients with CTEPH was demonstrated, two important issues remain unresolved. The cause of gut dysbiosis in patients with CTEPH is unclear in this study. Dietary habit is an important factor for the alteration of gut microbiota [14, 44]. However, our results regarding the dietary habits suggested that there was no difference in the dietary intake between patients with CTEPH and the control participants and, the effect of diet on gut dysbiosis was limited. PPI treatments can also affect the composition of gut microbiota [49]. More patients with CTEPH used PPI than the control participants in this study; however, the effect on gut dysbiosis could not be evaluated because of the small sample size. Further, this might also have some effects on the gut dysbiosis. In addition, whether gut dysbiosis is a cause or a result of CTEPH remains unclear. It was reported that heart failure and the induced congestion can be related to the alteration of gut microbiota and increased gut permeability [50]. Therefore, it is possible that gut dysbiosis is the result of right heart failure resulting from CTEPH. To solve these issues, it may be helpful to compare patients with CTEPH and acute pulmonary embolism and patients with right heart dysfunction due to CTEPH and other causes.

This study has several limitations. First, the sample size was small. Second, all patients with CTEPH and the control participants in this study were Japanese. Variations in resitential areas and the differences in the dietary habits can affect the characteristics of human gut microbiota [51]; therefore, whether the effect of dysbiosis in patients with CTEPH is global remains unclear. Third, this was an observational study; therefore, it is still unclear whether gut dysbiosis is a cause or a result of CTEPH as described above. Fourth, the time points during the day and the technique of collecting fecal samples during the day depended on the participant’s decision, which might have affected the results. Despite these limitations, we believe that our results suggest the presence of gut dysbiosis in patients with CTEPH and provide important information for understanding the pathogenesis of CTEPH.

Conclusion

Our findings suggest that patients with CTEPH have gut dysbiosis that can be related to the elevation of endotoxin and inflammatory cytokine levels. The results of this study may provide new perspectives for understanding the pathogenesis of CTEPH.

Availability of data and materials

All microbiome next-generation sequencing data files are available from the Sequence Read Archive database (Patients with CTEPH: PRJNA773643, and control participants: DRR247496, DRR247580, DRR247428, DRR247444, DRR247558, DRR247431, DRR247378, DRR247387, DRR247546, DRR247376, DRR247625, DRR247643, DRR247526, DRR247538, DRR247540, DRR247696, DRR248098, DRR247938, DRR247804, DRR247769, DRR247960, DRR247775). The other datasets used in the current study are available from the corresponding author on reasonable request.

Abbreviations

CTEPH:

chronic thromboembolic pulmonary hypertension

PH:

pulmonary hypertension

PAH:

pulmonary arterial hypertension

BMI:

body mass index

DNA:

deoxyribose nucleic acid

rRNA:

ribosomal ribonucleic acid

PCR:

polymerase chain reaction

OTU:

operational taxonomic unit

PCoA:

principal coordinate analysis

BDHQ:

brief self-administered diet history questionnaire

TNF-α:

tumor necrosis factor-α

IL:

interleukin

MIP:

macrophage inflammatory protein

NFκB:

nuclear factor-kappa B

PPI:

proton pump inhibitor

References

  1. Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53:1801915. https://doi.org/10.1183/13993003.01915-2018.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, et al. ERS Statement on chronic thromboembolic pulmonary hypertension. Eur Respir J. 2021;57:2002828. https://doi.org/10.1183/13993003.02828-2020.

    Article  PubMed  Google Scholar 

  3. Lang IM. Chronic thromboembolic pulmonary hypertension: a distinct disease entity. Eur Respir Rev. 2015;24:246–52. https://doi.org/10.1183/16000617.00001115.

    Article  PubMed  Google Scholar 

  4. Delcroix M, Lang IM, Pepke-Zaba J, Jansa P, D’Armini AM, Snijder R, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation. 2016;133:859–71. https://doi.org/10.1161/circulationaha.115.016522.

    Article  CAS  PubMed  Google Scholar 

  5. Miwa H, Tanabe N, Jujo T, Kato F, Anazawa R, Yamamoto K, et al. Long-term outcome of chronic thromboembolic pulmonary hypertension at a single Japanese pulmonary endarterectomy center. Circ J. 2018;82:1428–36. https://doi.org/10.1253/circj.CJ-17-1242.

    Article  PubMed  Google Scholar 

  6. Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J. 2013;41:462–8. https://doi.org/10.1183/09031936.00049312.

    Article  PubMed  Google Scholar 

  7. Bonderman D, Jakowitsch J, Adlbrecht C, Schemper M, Kyrle PA, Schönauer V, et al. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thromb Haemost. 2005;93:512–6. https://doi.org/10.1160/th04-10-0657.

    Article  CAS  PubMed  Google Scholar 

  8. Bonderman D, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Dunkler D, Taghavi S, et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation. 2007;115:2153–8. https://doi.org/10.1161/circulationaha.106.661041.

    Article  PubMed  Google Scholar 

  9. Zabini D, Heinemann A, Foris V, Nagaraj C, Nierlich P, Bálint Z, et al. Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients. Eur Respir J. 2014;44:951–62. https://doi.org/10.1183/09031936.00145013.

    Article  CAS  PubMed  Google Scholar 

  10. von Haehling S, von Bardeleben RS, Kramm T, Thiermann Y, Niethammer M, Doehner W, et al. Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension. Int J Cardiol. 2010;144:206–11. https://doi.org/10.1016/j.ijcard.2009.04.019.

    Article  Google Scholar 

  11. Koudstaal T, van Uden D, van Hulst JAC, Heukels P, Bergen IM, Geenen LW, et al. Plasma markers in pulmonary hypertension subgroups correlate with patient survival. Respir Res. 2021;22:137. https://doi.org/10.1186/s12931-021-01716-w.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Quarck R, Wynants M, Verbeken E, Meyns B, Delcroix M. Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension. Eur Respir J. 2015;46:431–43. https://doi.org/10.1183/09031936.00009914.

    Article  CAS  PubMed  Google Scholar 

  13. Neves AL, Coelho J, Couto L, Leite-Moreira A, Roncon-Albuquerque R Jr. Metabolic endotoxemia: a molecular link between obesity and cardiovascular risk. J Mol Endocrinol. 2013;51:R51–64. https://doi.org/10.1530/jme-13-0079.

    Article  CAS  PubMed  Google Scholar 

  14. Battson ML, Lee DM, Weir TL, Gentile CL. The gut microbiota as a novel regulator of cardiovascular function and disease. J Nutr Biochem. 2018;56:1–15. https://doi.org/10.1016/j.jnutbio.2017.12.010.

    Article  CAS  PubMed  Google Scholar 

  15. Moludi J, Maleki V, Jafari-Vayghyan H, Vaghef-Mehrabany E, Alizadeh M. Metabolic endotoxemia and cardiovascular disease: a systematic review about potential roles of prebiotics and probiotics. Clin Exp Pharmacol Physiol. 2020;47:927–39. https://doi.org/10.1111/1440-1681.13250.

    Article  CAS  PubMed  Google Scholar 

  16. Emoto T, Yamashita T, Sasaki N, Hirota Y, Hayashi T, So A, et al. Analysis of gut microbiota in coronary artery disease patients: a possible link between gut microbiota and coronary artery disease. J Atheroscler Thromb. 2016;23:908–21. https://doi.org/10.5551/jat.32672.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Hayashi T, Yamashita T, Watanabe H, Kami K, Yoshida N, Tabata T, et al. Gut microbiome and plasma microbiome-related metabolites in patients with decompensated and compensated heart failure. Circ J. 2018;83:182–92. https://doi.org/10.1253/circj.CJ-18-0468.

    Article  PubMed  Google Scholar 

  18. Sharma RK, Oliveira AC, Yang T, Karas MM, Li J, Lobaton GO, et al. Gut pathology and its rescue by ACE2 (angiotensin-converting enzyme 2) in hypoxia-induced pulmonary hypertension. Hypertension. 2020;76:206–16. https://doi.org/10.1161/hypertensionaha.120.14931.

    Article  CAS  PubMed  Google Scholar 

  19. Sharma RK, Oliveira AC, Yang T, Kim S, Zubcevic J, Aquino V, et al. Pulmonary arterial hypertension-associated changes in gut pathology and microbiota. ERJ Open Res. 2020;6:00253–2019. https://doi.org/10.1183/23120541.00253-2019.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Callejo M, Mondejar-Parreno G, Barreira B, Izquierdo-Garcia JL, Morales-Cano D, Esquivel-Ruiz S, et al. Pulmonary arterial hypertension affects the rat gut microbiome. Sci Rep. 2018;8:9681. https://doi.org/10.1038/s41598-018-27682-w.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Sanada TJ, Hosomi K, Shoji H, Park J, Naito A, Ikubo Y, et al. Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model. Pulm Circ. 2020;10:2045894020929147. https://doi.org/10.1177/2045894020929147.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Kim S, Rigatto K, Gazzana MB, Knorst MM, Richards EM, Pepine CJ, et al. Altered gut microbiome profile in patients with pulmonary arterial hypertension. Hypertension. 2020;75:1063–71. https://doi.org/10.1161/hypertensionaha.119.14294.

    Article  CAS  PubMed  Google Scholar 

  23. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46:903–75. https://doi.org/10.1183/13993003.01032-2015.

    Article  CAS  PubMed  Google Scholar 

  24. Park J, Kato K, Murakami H, Hosomi K, Tanisawa K, Nakagata T, et al. Comprehensive analysis of gut microbiota of a healthy population and covariates affecting microbial variation in two large Japanese cohorts. BMC Microbiol. 2021;21:151. https://doi.org/10.1186/s12866-021-02215-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Tabata T, Yamashita T, Hosomi K, Park J, Hayashi T, Yoshida N, et al. Gut microbial composition in patients with atrial fibrillation: effects of diet and drugs. Heart Vessels. 2021;36:105–14. https://doi.org/10.1007/s00380-020-01669-y.

    Article  PubMed  Google Scholar 

  26. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335–6. https://doi.org/10.1038/nmeth.f.303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Mohsen A, Park J, Chen YA, Kawashima H, Mizuguchi K. Impact of quality trimming on the efficiency of reads joining and diversity analysis of Illumina paired-end reads in the context of QIIME1 and QIIME2 microbiome analysis frameworks. BMC Bioinformatics. 2019;20:581. https://doi.org/10.1186/s12859-019-3187-5.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2013;41:D590–6. https://doi.org/10.1093/nar/gks1219.

    Article  CAS  PubMed  Google Scholar 

  29. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics. 2011;27:2194–200. https://doi.org/10.1093/bioinformatics/btr381.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kuhn M. Building predictive models in R using the caret package. J Stat Softw. 2008;28:26. https://doi.org/10.18637/jss.v028.i05.

    Article  Google Scholar 

  31. Kursa MB, Rudnicki WR. Feature selection with the Boruta package. J Stat Softw. 2010;36:13. https://doi.org/10.18637/jss.v036.i11.

    Article  Google Scholar 

  32. Kobayashi S, Murakami K, Sasaki S, Okubo H, Hirota N, Notsu A, et al. Comparison of relative validity of food group intakes estimated by comprehensive and brief-type self-administered diet history questionnaires against 16 d dietary records in Japanese adults. Public Health Nutr. 2011;14:1200–11. https://doi.org/10.1017/s1368980011000504.

    Article  PubMed  Google Scholar 

  33. Kobayashi S, Honda S, Murakami K, Sasaki S, Okubo H, Hirota N, et al. Both comprehensive and brief self-administered diet history questionnaires satisfactorily rank nutrient intakes in Japanese adults. J Epidemiol. 2012;22:151–9. https://doi.org/10.2188/jea.je20110075.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Yang M, Deng C, Wu D, Zhong Z, Lv X, Huang Z, et al. The role of mononuclear cell tissue factor and inflammatory cytokines in patients with chronic thromboembolic pulmonary hypertension. J Thromb Thrombolysis. 2016;42:38–45. https://doi.org/10.1007/s11239-015-1323-2.

    Article  CAS  PubMed  Google Scholar 

  35. Soon E, Holmes AM, Barker L, Treacy C, Suntharalingham J, Toshner M, et al. S97 Inflammatory cytokines are elevated in patients with operable chronic thromboembolic pulmonary hypertension and predict outcome post-endarterectomy. Thorax. 2010;65:A45. https://doi.org/10.1136/thx.2010.150938.48.

    Article  Google Scholar 

  36. Bochenek ML, Rosinus NS, Lankeit M, Hobohm L, Bremmer F, Schütz E, et al. From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension. Thromb Haemost. 2017;117:769–83. https://doi.org/10.1160/th16-10-0790.

    Article  PubMed  Google Scholar 

  37. Naito A, Sakao S, Terada J, Iwasawa S, Jujo Sanada T, Suda R, et al. Nocturnal hypoxemia and high circulating TNF-α levels in chronic thromboembolic pulmonary hypertension. Intern Med. 2020;59:1819–26. https://doi.org/10.2169/internalmedicine.4458-20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ranchoux B, Bigorgne A, Hautefort A, Girerd B, Sitbon O, Montani D, et al. Gut-lung connection in pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2017;56:402–5. https://doi.org/10.1165/rcmb.2015-0404LE.

    Article  CAS  PubMed  Google Scholar 

  39. Chakaroun RM, Massier L, Kovacs P. Gut microbiome, intestinal permeability, and tissue bacteria in metabolic disease: perpetrators or bystanders? Nutrients. 2020;12:1082. https://doi.org/10.3390/nu12041082.

    Article  CAS  PubMed Central  Google Scholar 

  40. Leclercq S, Matamoros S, Cani PD, Neyrinck AM, Jamar F, Stärkel P, et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci U S A. 2014;111:E4485–93. https://doi.org/10.1073/pnas.1415174111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Hiippala K, Jouhten H, Ronkainen A, Hartikainen A, Kainulainen V, Jalanka J, et al. The potential of gut commensals in reinforcing intestinal barrier function and alleviating inflammation. Nutrients. 2018;10:988. https://doi.org/10.3390/nu10080988.

    Article  CAS  PubMed Central  Google Scholar 

  42. Shen Z, Zhu C, Quan Y, Yang J, Yuan W, Yang Z, et al. Insights into Roseburia intestinalis which alleviates experimental colitis pathology by inducing anti-inflammatory responses. J Gastroenterol Hepatol. 2018;33:1751–60. https://doi.org/10.1111/jgh.14144.

    Article  CAS  PubMed  Google Scholar 

  43. Jin M, Kalainy S, Baskota N, Chiang D, Deehan EC, McDougall C, et al. Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids. Liver Int. 2019;39:1437–47. https://doi.org/10.1111/liv.14106.

    Article  CAS  PubMed  Google Scholar 

  44. Fukui H. Role of gut dysbiosis in liver diseases: what have we learned so far? Diseases. 2019;7:58. https://doi.org/10.3390/diseases7040058.

    Article  CAS  PubMed Central  Google Scholar 

  45. Jia Z, Huang Y, Ji X, Sun J, Fu G. Ticagrelor and clopidogrel suppress NF-κB signaling pathway to alleviate LPS-induced dysfunction in vein endothelial cells. BMC Cardiovasc Disord. 2019;19:318. https://doi.org/10.1186/s12872-019-01287-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Smolders VFED, Lodder K, Rodríguez C, Tura-Ceide O, Barberà JA, Jukema JW, et al. The inflammatory profile of CTEPH-derived endothelial cells is a possible driver of disease progression. Cells. 2021;10:737. https://doi.org/10.3390/cells10040737.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Wynants M, Vengethasamy L, Ronisz A, Meyns B, Delcroix M, Quarck R. NF-κB pathway is involved in CRP-induced effects on pulmonary arterial endothelial cells in chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2013;305:L934–42. https://doi.org/10.1152/ajplung.00034.2013.

    Article  CAS  PubMed  Google Scholar 

  48. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72. https://doi.org/10.2337/db06-1491.

    Article  CAS  PubMed  Google Scholar 

  49. Imhann F, Bonder MJ, Vila VA, Fu J, Mujagic Z, Vork L, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740–8. https://doi.org/10.1136/gutjnl-2015-310376.

    Article  CAS  PubMed  Google Scholar 

  50. Nagatomo Y, Tang WH. Intersections between microbiome and heart failure: revisiting the gut hypothesis. J Card Fail. 2015;21:973–80. https://doi.org/10.1016/j.cardfail.2015.09.017.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Nishijima S, Suda W, Oshima K, Kim SW, Hirose Y, Morita H, et al. The gut microbiome of healthy Japanese and its microbial and functional uniqueness. DNA Res. 2016;23:125–33. https://doi.org/10.1093/dnares/dsw002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Dr. Haruka Murakami for collecting data of dietary habits. Editage (www.editage.com) contributed to the English-language editing of this manuscript.

Funding

This study was supported by a Grant-in-Aid for Scientific Research C from the Japan Society for the Promotion of Science (JSPS) (No. 17K09604 and 20K08534), the Japan Agency for Medical Research and Development (AMED) (No. JP20gm1010006h0004), the Ministry of Health and Welfare of Japan and Public /Private R&D Investment Strategic Expansion PrograM: PRISM (No. 20AC5004). The funders had no role in the study design, data collection or analysis, decision to publish, or in the preparation of the manuscript.

Author information

Author notes

  1. Yumiko Ikubo and Takayuki Jujo Sanada have contributed equally to this work

Authors and Affiliations

  1. Department of Respirology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-Ku, Chiba City, 260-8670, Japan

    Yumiko Ikubo, Takayuki Jujo Sanada, Akira Naito, Hiroki Shoji, Tomoko Misawa, Rika Suda, Ayumi Sekine, Toshihiko Sugiura, Ayako Shigeta, Seiichiro Sakao, Nobuhiro Tanabe, Takuji Suzuki & Koichiro Tatsumi

  2. Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health, and Nutrition, Osaka, Japan

    Koji Hosomi & Jun Kunisawa

  3. Laboratory of Bioinformatics, Artificial Intelligence Center for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan

    Jonguk Park & Kenji Mizuguchi

  4. Department of Respirology, Chibaken Saiseikai Narashino Hospital, Narashino, Japan

    Rika Suda & Nobuhiro Tanabe

  5. Section of Energy Metabolism, Department of Nutrition and Metabolism, National Institute of Biomedical Innovation, Health and Nutrition, Tokyo, Japan

    Hinako Nanri

  6. Institute for Protein Research, Osaka University, Osaka, Japan

    Kenji Mizuguchi

Authors
  1. Yumiko Ikubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takayuki Jujo Sanada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koji Hosomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jonguk Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akira Naito
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroki Shoji
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomoko Misawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rika Suda
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ayumi Sekine
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Toshihiko Sugiura
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ayako Shigeta
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hinako Nanri
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Seiichiro Sakao
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Nobuhiro Tanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Kenji Mizuguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Jun Kunisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Takuji Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Koichiro Tatsumi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TJS, KH, JP, NT, JK were involved in study design, data interpretation and analysis. YI, AN, HS, TM, RS, AS, TS, AS, HS, SS, TS, KT were involved in the aquisition of the clinical data and data analysis. KH, JP, KM, JK analyzed data of gut microbiota. HN was involved in the ananysis of nutrition intake. YI, TJS, KH, JP wrote the main manuscript. SS, NT, JT, ST, KT critically revised the drafts. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Takayuki Jujo Sanada.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Chiba University (approval number 2414) and the National Institutes of Biomedical Innovation, Health and Nutrition (approval number 171–02), and was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent to participate in the study.

Consent for publication

Not applicable.

Competing interests

There are no conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Dietary intake comparison analysis between patients with CTEPH and control participants. CTEPH: chronic thromboembolic pulmonary hypertansion; FDR: false discovery rate.

Additional file 2.

Univariate analysis for overall microbiome community variation using the envfit function. FDR: false discovery rate.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ikubo, Y., Sanada, T.J., Hosomi, K. et al. Altered gut microbiota and its association with inflammation in patients with chronic thromboembolic pulmonary hypertension: a single-center observational study in Japan. BMC Pulm Med 22, 138 (2022). https://doi.org/10.1186/s12890-022-01932-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12890-022-01932-0

Keywords

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us